Agilent Technologies, Inc. · NYSE:A
Agilent Technologies — Q2 2020 Earnings Presentation
8 slides from Agilent Technologies's earnings presentation, Sep 23, 2020
Slide 1: Agilent Technologies Q2'20 Results Presentation
Agilent Technologies Q2'20 Results Presentation
Slide 2: Safe Harbor
Safe Harbor This presentation contains forward-looking statements (including, without limitation, information on the company’s goals, priorities, revenue, revenue growth, earnings per share, operating margin, operating cash flow, capital expenditures, capital allocation, growth opportunities, new pr
Slide 3: Agilent Results Q2'20
Agilent Results Q2'20 Scale and leading technology across Analytical Laboratories and Clinical & Dx markets Q2'20 Financial Metrics Q2'20 Highlights • Revenues: $1.24B, -1.7% y/y core(1)(2), • Revenue: +MSD growth in Pharma and Dx&C markets flat y/y reported (+3.3% M&A, -1.6% FX). more than offset b
Slide 4: Life Sciences & Applied Markets Group (LSAG)
Life Sciences & Applied Markets Group (LSAG) • Revenue performance reflected the expanding Instrumentation and Informatics for Analytical Laboratories impact of global pandemic, most notably on A&G and C&E markets. China and Food both grew. • BioTek fared well in the face of lab closures and core Ce
Slide 5: Agilent Cross Lab Group (ACG)
Agilent Cross Lab Group (ACG) Analytical Laboratory • Core growth led by Pharma and Environmental & Consumables and Services Forensics. All other markets saw declines, largely due to COVID-19 headwinds. • ACG grew in the high-single-digits in China, finishing the quarter strongly as customers began
Slide 6: Diagnostics and Genomics Group (DGG)
Diagnostics and Genomics Group (DGG) • Core revenue growth driven by continued strong Pathology, Genomics, and Nucleic Acid Manufacturing Pharma partially offset by declines in A&G Research. • New Frederick, Colorado NASD manufacturing site continues to ramp in-line with expectations. NGS Target Enr
Slide 7: Q2'20 Results by End Market
Q2'20 Results by End Market Analytical Laboratory End Markets Chemical & Energy Q2'20 revenues: -3% y/y on core(2) basis 22% Pharma & Biotech Pharma & Biotech: Up 5% with strength in Bio-Pharma, 32% Services, Chemistries and Consumables, and NASD. Food 9% Academia & Govt: Down 16% as universit
Slide 8: Agilent's Response to COVID-19
Agilent’s Response to COVID-19 “During this challenging time, Agilent's focus is on four key areas. The first is ensuring the health and safety of the Agilent team and their loved ones. Second, is our unwavering commitment to our customers. From the early stages of the pandemic, we took decisive act